The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | NSCLC highlights at ESMO 2025: OptiTROP-Lung04 and HARMONi-6
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, discusses key lung cancer trials from the European Society for Medical Oncology (ESMO) 2025 Congress, including the OptiTROP-Lung04 trial of sacituzumab tirumotecan in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) and the HARMONi-6 trial NCT05840016) of ivonescimab versus tislelizumab with chemotherapy in advanced squamous NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this has been a very busy congress and very important in terms of lung cancer as you know in the presidential session we had two potentially practice-changing studies the one being sacituzumab tirumotecan in the second line treatment of patients with advanced EGFR positive non-small cell lung cancer harboring classical activating mutation, where sacituzumab tirumotecan an ADC has been shown to be superior in terms of PFS as compared to standard chemotherapy...
So this has been a very busy congress and very important in terms of lung cancer as you know in the presidential session we had two potentially practice-changing studies the one being sacituzumab tirumotecan in the second line treatment of patients with advanced EGFR positive non-small cell lung cancer harboring classical activating mutation, where sacituzumab tirumotecan an ADC has been shown to be superior in terms of PFS as compared to standard chemotherapy. Second, another important trial that was read out in the presidential session was HARMONi-6, where we saw for the first time the combination of platinum-based chemotherapy plus ivonescimab, which is not correct it is actually a bispecific antibody targeting both PD-L1 and VEGFA, showing significantly superior progression-free survival as compared to standard platinum-based chemotherapy plus Pembrolizumab in patients with advanced squamous non-small cell lung cancer in an Asian population and we’re really looking forward to the readout of the large registrational trial in the first-line setting which is HARMONi-3.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
